Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00872521 · OUTCOME

Overall Survival (OS) Stratified by Protein Expression (Bcl-2)

A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma · Source last updated 2014-05-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
2 years after Day 1 Cycle 1 of PAD

What was measured

Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (bcl-2).

Analysis population: Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The OS was not imputed.

Groups in this outcome

Negative

Participants without bcl-2 expression

Positive

Participants with bcl-2 expression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Negative12
Positive66

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Negative91.7Not reportedNot reportedNot reportedNot reported
Positive90.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        91.7
      2. group Id
        OG001
        value
        90.9
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    2. group Id
      OG001
      value
      66
    units
    Participants
description
Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (bcl-2).
groups
  1. description
    Participants without bcl-2 expression
    id
    OG000
    title
    Negative
  2. description
    Participants with bcl-2 expression
    id
    OG001
    title
    Positive
param Type
NUMBER
population Description
Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The OS was not imputed.
reporting Status
POSTED
time Frame
2 years after Day 1 Cycle 1 of PAD
title
Overall Survival (OS) Stratified by Protein Expression (Bcl-2)
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice